$TWST

Finn Patrick John sold $246K of TWST

Finn Patrick John (President and COO) sold 2,888 shares of Twist Bioscience Corp (TWST) at $85.32 ($0.25M total) on 2026-08-03.

Original reporting
SEC EDGAR · Finn Patrick John
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around TWST due to insider selling, but there is no new operational, financial, or regulatory information in the text.

02

Market read

A single insider open-market sale is disclosed, which can slightly affect sentiment but is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

No 10b5-1 plan is stated, but the filing does not explain motive; also, insider sales can be frequent and not correlated with near-term fundamentals without accompanying buys, guidance changes, or operational events.

Relevance 4/10Novelty 3/10Timing: filed Aug 5, transaction dated Aug 3 (after-hours/next session context)

Background

The article is an SEC Form 4 insider transaction disclosure for Twist Bioscience, reported via SEC EDGAR.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience Form 4 shows COO Finn Patrick John sold 2,888 shares for about $246.4K at $85.3212 on Aug 3.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other news.

Evidence & confidence

The filing is primary-source and company-specific, but insider sales alone usually do not change earnings power or guidance. The absence of a disclosed 10b5-1 plan can add minor interpretive noise, yet the transaction size is modest relative to a large-cap context and no other operational catalyst is provided.

Market effects

Minimal. Insider sale does not provide new biotech/biomanufacturing sector information.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification, taxes, or pre-planned personal liquidity needs, so it may not reflect negative company expectations.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider transaction disclosure.

  • Finn Patrick John

    President and COO who sold 2,888 shares of TWST.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.